Graded Treatment Strategies for Hemophagocytic Lymphohistiocytosis (HLH) Based on Disease Severity and Triggers

Initial Treatment Decision

Initiation of HLH‑directed therapy should be guided by the presence of organ dysfunction rather than solely by meeting diagnostic criteria. 1

Immediate administration of etoposide is mandatory for patients with severe HLH and imminent organ failure. 1
The backbone regimen consists of dexamethasone 10 mg/m² combined with etoposide (modified HLH‑94 protocol). 1, 2
Etoposide dose should be reduced in the setting of renal impairment, but no adjustment is required for isolated hyperbilirubinemia or elevated transaminases. 1
Cumulative etoposide exposure should be kept below 2–3 g/m² to lower the risk of secondary malignancy, especially in non‑malignant HLH. 2

Pulsed corticosteroids (prednisolone 1–2 mg/kg or dexamethasone 5–10 mg/m²) may be sufficient without etoposide. 3
Adding intravenous immunoglobulin (IVIG) 1.6 g/kg divided over 2–3 days can provide additional anti‑inflammatory effect. 1, 4
Weekly reassessment is essential to determine whether escalation to etoposide is required. 1

The standard course for secondary HLH is 8 weeks of etoposide, but continuation should be re‑evaluated weekly rather than assumed automatically. 1, 4
Patients with residual disease after 8 weeks benefit from maintenance therapy with cyclosporine A (or tacrolimus) and may be considered for allogeneic stem cell transplantation. 1, 5
When a genetic mutation mandates transplantation, HLH‑94‑based maintenance therapy is recommended after the initial 8‑week induction. 2

Rapid clinical deterioration in treatment‑naïve EBV‑HLH requires immediate etoposide without delay. 3, 4
Rituximab 375 mg/m² weekly for 2–4 doses should be added to eradicate the B‑cell viral reservoir. 3, 5
Rituximab cannot replace anti‑T‑cell therapy (corticosteroids ± etoposide) because EBV‑HLH often involves T‑cell/NK‑cell infection. 3
Serial monitoring of EBV DNA, ferritin, soluble CD25, and blood counts guides treatment duration. 3, 4
Persistent elevation of EBV DNA should prompt consideration of allogeneic stem cell transplantation. 3

Distinguish “malignancy‑triggered HLH” (present at diagnosis/relapse) from “HLH during chemotherapy” (infection‑related) as therapeutic approaches differ. 3, 4
For HLH occurring during chemotherapy, use corticosteroids (prednisolone 1–2 mg/kg or dexamethasone 5–10 mg/m²) with optional IVIG; etoposide should be used sparingly to preserve bone‑marrow recovery. 3
In malignancy‑triggered HLH, definitive treatment of the underlying malignancy is the primary strategy. 3

Anakinra (IL‑1 inhibition) may reduce mortality in sepsis patients with MAS features and can be considered when steroids are insufficient. 1, 4

Broad antimicrobial prophylaxis is mandatory for all patients receiving HLH‑directed therapy due to profound immunosuppression. 1, 6
Specific prophylaxis includes:
- Pneumocystis jirovecii (required) – 5
- Antifungal agents (required) – 4
- Antiviral agents (recommended because of severe T‑cell depletion) – 5
Hospitalization in HEPA‑filtered units should be considered for high‑risk patients. 1, 6

Perform weekly assessments of ferritin, soluble CD25, complete blood counts, and trigger‑specific markers (e.g., EBV DNA). 3, 4
Vigilantly monitor for secondary infections, a leading cause of mortality in HLH. 1
Watch for prolonged cytopenias after chemotherapy and persistent fever despite antibiotics as signals of treatment failure or complications. 6, 5

Achieving inactive HLH status before transplantation is strongly associated with improved survival. 1, 2
Candidates for transplant include primary (genetic) HLH and severe or persistent secondary HLH. 1, 2
Both reduced‑intensity conditioning (RIC) and myeloablative conditioning (MAC) are acceptable; no clear superiority of one over the other has been demonstrated in adults. 1, 2
HLA‑matched relatives should be screened for the same pathogenic mutations to avoid transplanting defective donor cells. 1, 2

Ruxolitinib (JAK2 inhibitor) is used off‑label to reduce cytokine‑driven inflammation in refractory HLH. 2
Alemtuzumab (anti‑CD52 antibody) is an option for refractory cases unresponsive to standard therapy. 2

Do not delay etoposide in severe HLH with organ failure; mortality is extremely high without prompt treatment. 1, 3
IVIG should not be used as monotherapy because its efficacy is uncertain, especially in adult‑onset Still’s disease. 1, 4
Failure to provide infection prophylaxis markedly increases the risk of fatal secondary infections. 1, 6
Avoid automatic continuation of etoposide for the full 8‑week course without weekly reassessment of necessity. 1
Do not proceed to transplantation while HLH remains active; disease control must be achieved first. 1, 2